Auh June-Sun – Chairman, Ahngook Pharm, South Korea
Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers?…
The Korea Pharmaceutical Manufacturers Association, since its foundation in 1945, along with pharmaceutical companies, has been committed to improve healthcare for all mankind and develop pharmaceutical industry.
With about 190 member companies, KPMA expanded R&D investments since the implementation of Drug Substance Patent Law in 1987 to place Korea in the world’s 10th country to commercialize new molecular entities in 2003. Up until the end of 2008, 14 new molecular entities products were developed in the country, with 45 projects from 29 companies undergoing clinical studies, 61 potential candidates currently under new drugs development phases and 40 cases of licensing out in 14 countries.
In order to manufacture safe medicines of the highest quality, 65 companies collectively invested 2 trillion won to upgrade manufacturing plants in compliance with c-GMP standards. In addition, to increase credibility in the international pharmaceutical market, Fair Competition Committee was established and Hotline Reporting Center for code compliance complaints was activated to escalate efforts in making all transaction as fair as possible. Market size of Korean pharmaceutical industry, gauged by values of drugs manufactured, in 2000 was 7.89 trillion won and the size grew substantially to 13.43 trillion won in 2007, almost doubling the size. Such a significant increase is attributed to rapid aging of the population, external and political factors that favorably affected the industry as well as continuous investments in R&D and GMP upgrades.
KPMA aims to strengthen collaboration of Korean companies with pharmaceutical companies already having experience in product launches in the overseas markets.
Contact details
161 Hyoryeong-ro, Seocho-gu, Seoul 137-849 Korea
TEL: +82 2 581 2101 / 2102
FAX: +82 2 581 2106
http://www.kpma.or.kr
kpma@kpma.or.kr
Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers?…
Lee Kyoung-Ryul has served as Chairman of SCL Healthcare Group since 2007. He discusses the diagnostic service providers’ extensive network in Korea as well as their ambitious plans to export…
On February second, the Korean Ministry of Health and Welfare announced the start of a second round of financing to the biopharmaceutical industry, as part of the Global Pharmaceutical Industry…
With a wealth of experience in different countries around the world, Christophe Piganiol came to Korea as general manager of Zuellig Pharma in 2010. Today he discusses the importance of…
Brian Wang, CEO of Korean super-generics developer GL PharmTech, discusses Korea’s relative strengths in different stages of R&D, and how this motivated the foundation and evolution of GL PharmTech. What…
Liz Chatwin came to Korea as general manager of AstraZeneca in the fall of 2013, following a period working at the company’s Chinese affiliate for several years. She contrasts the…
Lee Han-Koo, president of Daehwa Pharmaceutical, explains his strategy to corner the transdermal drug delivery system (TDDS) market through innovative patch products as well as a special focus on oral…
James Jun, CEO of KT&G Life Sciences, discusses his company’s new entry into the Korean pharma market and the role that the KT&G brand can play in accelerating its drug…
Korean success story Boryung has a goal to become the number one domestic pharmaceutical company in the coming years. The company’s CEO, Choi Tae-Hong, discusses this strategy and the victory…
Bae Byoung-Jun, director general of the Bureau of Health Industry at Korea’s Ministry of Health and Welfare, outlines the history and structure of the Korean healthcare system and highlights the…
LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth…
Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of…
See our Cookie Privacy Policy Here
